Terms: = Brain cancer AND TPM4, P67936, 7171, ENSG00000167460
6 results:
1. Lorlatinib for the treatment of inflammatory myofibroblastic tumour with tpm4-ALK fusion following failure of entrectinib.
Wong HH; Bentley H; Bulusu VR; Anyaegbu G; Watkins J; Horan G; Hatcher H
Anticancer Drugs; 2020 Nov; 31(10):1106-1110. PubMed ID: 32868646
[TBL] [Abstract] [Full Text] [Related]
2. Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
Hanna C; Kurian KM; Williams K; Watts C; Jackson A; Carruthers R; Strathdee K; Cruickshank G; Dunn L; Erridge S; Godfrey L; Jefferies S; McBain C; Sleigh R; McCormick A; Pittman M; Halford S; Chalmers AJ
Neuro Oncol; 2020 Dec; 22(12):1840-1850. PubMed ID: 32347934
[TBL] [Abstract] [Full Text] [Related]
3. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract] [Full Text] [Related]
4. Differences in Protein Expression between the U251 and U87 Cell Lines.
Li H; Lei B; Xiang W; Wang H; Feng W; Liu Y; Qi S
Turk Neurosurg; 2017; 27(6):894-903. PubMed ID: 27651343
[TBL] [Abstract] [Full Text] [Related]
5. Targeted next-generation sequencing panel (GlioSeq) provides comprehensive genetic profiling of central nervous system tumors.
Nikiforova MN; Wald AI; Melan MA; Roy S; Zhong S; Hamilton RL; Lieberman FS; Drappatz J; Amankulor NM; Pollack IF; Nikiforov YE; Horbinski C
Neuro Oncol; 2016 Mar; 18(3):379-87. PubMed ID: 26681766
[TBL] [Abstract] [Full Text] [Related]
6. A retrospective analysis of recurrent intracranial ependymoma.
Antony R; Wong KE; Patel M; Olch AJ; McComb G; Krieger M; Gilles F; Sposto R; Erdreich-Epstein A; Dhall G; Gardner S; Finlay JL
Pediatr Blood Cancer; 2014 Jul; 61(7):1195-201. PubMed ID: 24615997
[TBL] [Abstract] [Full Text] [Related]
